Mereo BioPharma Group plc (NASDAQ:MREO) saw an upside of 14.52% to $1.42 after adding $0.18on Wednesday. The 5-day average trading volume is 699,268 shares of the company’s common stock. It has gained $1.4000 in the past week and touched a new high 2 times within the past 5 days. An average of 639,932 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,087,473.
MREO’s 1-month performance is 22.41% or $0.0750 on its low of $1.0950 reached on 07/25/23. The company’s shares have touched a 52-week low of $0.49 and high of $1.52, with the stock’s rally to the 52-week high happening on 06/15/23. YTD, MREO has achieved 89.33% or $0.6150 and has reached a new high 16 times. However, the current price is down -6.58% from the 52-week high price.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
MREO stock has a beta of 0.94.
Earnings Surprise
Net income grew 137.22% to -$34.2 million, while revenue of $0.0 was 100.0% off the previous quarter. MREO stock balance sheet for the recent quarter shows that total liabilities totaled 32.42 million, with total debt at $12.77 million.
Let’s look briefly at Mereo BioPharma Group plc (MREO) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 22 August was 68.08% to suggest the stock is trending Neutral, with historical volatility in this time period at 50.96%.
The stock’s 5-day moving average is $1.2710, reflecting a +6.64% or $0.0850 change from its current price. MREO is currently trading +18.70% above its 20-day SMA, +92.09% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +9.20% and SMA200 by+67.51%.
Stochastic %K and %D was 61.90% and 51.89% and the average true range (ATR) pointed at 0.0739. The RSI (14) points at 61.44%, while the 14-day stochastic is at 84.78% with the period’s ATR at 0.0760. The stock’s 9-day MACD Oscillator is pointing at 0.0200 and 0.0296 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Mereo BioPharma Group plc (NASDAQ: MREO), Cantor Fitzgerald launched coverage with an Overweight rating. Analysts offering their rating for MREO stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate MREO as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 2 have offered a “buy” rating.
What is MREO’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $4.00 and a high of $5.00, with their median price target at $4.50. Looking at these predictions, the average price target given by analysts is for Mereo BioPharma Group plc (MREO) stock is $4.50.
